BeOne Medicines Ltd. reported a modest expansion of its Hong Kong-listed equity base for March 2026, driven entirely by staff incentive programmes.

Key takeaways

1. Issued share capital • Ordinary shares in issue climbed by 0.74 million to 1.43 billion as of 31 March 2026, reflecting option exercises under the Fifth Amended and Restated 2018 Employee Share Purchase Plan. • No treasury shares were outstanding or transferred. • Gross proceeds from option exercises totalled USD 0.70 million.

2. Authorised capital unchanged • Authorised share count remained at 2.31 billion shares with aggregate authorised capital of USD 0.23 million. • The company’s Swiss-law “capital band” permits the board to adjust share capital between USD 0.14 million and USD 0.23 million through April 2029.

3. Share option activity • Under the Fourth Amended and Restated 2016 Share Option and Incentive Plan, 0.51 million options were granted, 0.68 million were cancelled and 0.62 million were adjusted for performance, leaving 29.46 million options outstanding. • The plan still allows a further 61.36 million shares to be issued upon future exercises.

4. Public float compliance • The company confirmed that its Hong Kong public float met the 25 % minimum threshold throughout the month.

5. Secondary RMB-denominated shares • The 115.06 million RMB shares listed on Shanghai’s STAR Market remained unchanged and are not fungible with the Hong Kong-listed ordinary shares.

No warrants, convertibles or other equity instruments were outstanding or exercised during the period.